Floatz logo

BELZUPACAP SAROTALOCAN

Indeterminate Lesions

Aura Biosciencesother_biologicalActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Indeterminate Lesions cohort.

Asset / SponsorPhaseRating
Bel-Sar
Aura Biosciences
Phase 3B

Same molecule, other indications

BELZUPACAP SAROTALOCAN is also rated in:

malignant choroid melanomaDormant
BB
Indicative ·
65 / 100
View asset →
ocular melanomaDormant
BB
Indicative ·
65 / 100
View asset →
uveal melanomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →